We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Watson is Second Drugmaker to Pull Generic Wellbutrin
Watson is Second Drugmaker to Pull Generic Wellbutrin
October 23, 2013
Watson is withdrawing from the market its 300 mg extended-release (ER) version of bupropion hydrochloride (HCl) after updated bioequivalence studies showed the drug is not therapeutically equivalent to its brand counterpart, Wellbutrin XL 300 mg.